Has Brandon Johnson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,855 in general payments to Brandon Johnson, MD across 98 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brandon Johnson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brandon Johnson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brandon Johnson, MD

Ophthalmology · New York, NYNPI 1386806693

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.

$2,855in general payments, 2019–2025

Across 98 payments — averaging $29.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sun Pharmaceutical Industries Inc.$389
Genentech USA, Inc.$359
Alcon$273
Mallinckrodt Hospital Products Inc.$217
Bausch & Lomb, A Division Of Bausch Health US, LLC$216
Novartis$216
plus $1K from 16 others

What the payments were for

Speaking & faculty fees$381%
Food & beverage$2,80298%
Entertainment$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sun Pharmaceutical Industries Inc.	11	$389
Genentech USA, Inc.	9	$359
Alcon	6	$273
Mallinckrodt Hospital Products Inc.	7	$217
Bausch & Lomb, A Division Of Bausch Health US, LLC	12	$216
Novartis	6	$216
AbbVie(2 entities)	8	$199
Regeneron Healthcare Solutions, Inc.	3	$163
Bausch & Lomb Americas Inc.	5	$103
Aerie Pharmaceuticals, Inc.	5	$102
ANI Pharmaceuticals, Inc.	3	$94
Oyster Point Pharma, Inc.	3	$67
Regeneron	1	$63
Eyevance Pharmaceuticals LLC	4	$61
Harrow Eye, LLC	2	$59
Sight Sciences, Inc.	2	$57
Alimera Sciences, Inc.	4	$53
Eyepoint US, Inc.	2	$47
Apellis Pharmaceuticals, Inc.	1	$44
Optos, Inc.	2	$30
Dompe US, Inc.	1	$26
Kala Pharmaceuticals, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,855 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024

$486,896

Medicare patients

125

Services billed

12,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	110	$4,053
Ketorolac Tromethamine	146	$2,366
Brimonidine Tartrate	13	$823
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	61	$595
Latanoprost	69	$426
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	28	$324
Ofloxacin	11	$240
Timolol Maleate	21	$141

Paid to pharmacies, not to this prescriber.

Other ophthalmology in New York

Nathan RadcliffeNew York$2.1M
Richard SpaideNew York$1.7M
Joshua YoungNew York$814K
Joseph PanarelliNew York$541K
Eric RosenbergNew York$434K
Michael CooneyNew York$398K
David GuyerNew York$322K
Ashley BrissetteNew York$315K
Jason SlakterNew York$272K
David ChuNew York$234K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →